Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Increased Early Mortality after Fludarabine and Melphalan Conditioning with Peripheral Blood Grafts in Haploidentical SCT with Post-Transplant Cyclophosphamide

Luke Eastburg, MD, David A. Russler-Germain, MDPhDBS, Ramzi Abboud, MD, Peter Westervelt, MD PhD, John F. DiPersio, MD PhD, Michael W. Becker, MD, Neha Kumar, MD, Omar S. Aljitawi, MD, Jeffrey R. Andolina, MD MS, Thomas J Fountaine, MD, Jane L. Liesveld, MD, Eric Huselton, MD

Blood (2019) 134 (Supplement_1): 4496.

https://doi.org/10.1182/blood-2019-129872

Published: 2019

Journal Articles

Tocilizumab Is Safe after T-Cell Replete Peripheral Blood Haploidentical Donor Transplantation

Ramzi Abboud, MD BS, Michael Slade, MDMS, Kathryn Trinkaus, PhD, Camille N. Abboud, MD, John F DiPersio, MD PhD, Todd A. Fehniger, MDPhD, Geoffrey L. Uy, MD, Peter Westervelt, MDPhD, Ravi Vij, MDMBA, Mark A. Schroeder, MD, Iskra Pusic, MD, Armin Ghobadi, MD, Rizwan Romee, MD

Blood (2017) 130 (Supplement 1): 3213.

https://doi.org/10.1182/blood.V130.Suppl_1.3213.3213

Published: 2017

Journal Articles

Pretransplant Clinical Factors Can be Used to Predict the Risk of Cytokine Release Syndrome after Haploidentical Peripheral Blood Transplantation

Ramzi Abboud, MD BS, Kathryn Trinkaus, PhD, John F DiPersio, MD PhD, Camille N. Abboud, MD, Rizwan Romee, MD

Blood (2017) 130 (Supplement 1): 1967.

https://doi.org/10.1182/blood.V130.Suppl_1.1967.1967

Published: 2017

Journal Articles

Hematopoietic Cell Transplant for Adults Age ≥65: Does Donor Type Matter?

Michael Slade, MDMS, Ramzi Abboud, MD BS, John F DiPersio, MD PhD, Peter Westervelt, MDPhD, Ravi Vij, MDMBA, Mark A. Schroeder, MD, Rizwan Romee, MD

Blood (2017) 130 (Supplement 1): 4575.

https://doi.org/10.1182/blood.V130.Suppl_1.4575.4575

Published: 2017

Journal Articles

Risk Factors for the Development of and Outcomes of Patients Who Develop Severe Cytokine Release Syndrome after Peripheral Blood Haploidentical Donor Transplant

Ramzi Abboud, MD, Michael Slade, BA, Wenners Ballard, III, MD, Jesse Keller, MD, John F DiPersio, MD PhD, Peter Westervelt, MD PhD, Camille N. Abboud, MD, Todd A Fehniger, MD PhD, Kathryn Trinkaus, Rizwan Romee, MD

Blood (2016) 128 (22): 3419.

https://doi.org/10.1182/blood.V128.22.3419.3419

Published: 2016

Journal Articles

T-Cell Replete Peripheral Blood Haploidentical Donor Transplant Is Frequently Associated with Cytokine Release Syndrome Which Responds to Anti-IL-6 Therapy

Ramzi Abboud, MD, Jesse Keller, MD, Michael Slade, BA, Michael P. Rettig, PhD, Stephanie Meier, John F. DiPersio, MD PhD, Todd A Fehniger, MD PhD, Kathryn Trinkaus, Geoffrey L. Uy, MD, Peter Westervelt, MD PhD, Ravi Vij, MD, Camille N. Abboud, MD FACP, Khoan Vu, MD, Pavan Kumar Bhamidipati, MBBS,MD, Rizwan Romee, MD

Blood (2015) 126 (23): 3106.

https://doi.org/10.1182/blood.V126.23.3106.3106

Published: 2015

NARROW

Increased Early Mortality after Fludarabine and Melphalan Conditioning with Peripheral Blood Grafts in Haploidentical SCT with Post-Transplant Cyclophosphamide

Tocilizumab Is Safe after T-Cell Replete Peripheral Blood Haploidentical Donor Transplantation

Pretransplant Clinical Factors Can be Used to Predict the Risk of Cytokine Release Syndrome after Haploidentical Peripheral Blood Transplantation

Hematopoietic Cell Transplant for Adults Age ≥65: Does Donor Type Matter?

Risk Factors for the Development of and Outcomes of Patients Who Develop Severe Cytokine Release Syndrome after Peripheral Blood Haploidentical Donor Transplant

T-Cell Replete Peripheral Blood Haploidentical Donor Transplant Is Frequently Associated with Cytokine Release Syndrome Which Responds to Anti-IL-6 Therapy

Email alerts

ASH Publications

American Society of Hematology

Increased Early Mortality after Fludarabine and Melphalan Conditioning with Peripheral Blood Grafts in Haploidentical SCT with Post-Transplant Cyclophosphamide

Tocilizumab Is Safe after T-Cell Replete Peripheral Blood Haploidentical Donor Transplantation

Pretransplant Clinical Factors Can be Used to Predict the Risk of Cytokine Release Syndrome after Haploidentical Peripheral Blood Transplantation

Hematopoietic Cell Transplant for Adults Age ≥65: Does Donor Type Matter?

Risk Factors for the Development of and Outcomes of Patients Who Develop Severe Cytokine Release Syndrome after Peripheral Blood Haploidentical Donor Transplant

T-Cell Replete Peripheral Blood Haploidentical Donor Transplant Is Frequently Associated with Cytokine Release Syndrome Which Responds to Anti-IL-6 Therapy

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only